Literature DB >> 3965585

Capnocytophaga species: infections in nonimmunocompromised and immunocompromised hosts.

D M Parenti, D R Snydman.   

Abstract

Retrospective review of isolates of Capnocytophaga, a genus of capnophilic gram-negative bacilli, referred to the Massachusetts State Laboratory Institute in Boston revealed 31 patients with infection due to Capnocytophaga, 16 in nonimmunocompromised hosts. These infections included empyema (three patients), lung abscess (one), sinusitis (one), conjunctivitis (three), subphrenic abscess (one), wound (three), osteomyelitis (one), and bacteremia (three). Two of the wound infections were closed-fist injuries involving bone or soft tissue. Capnocytophaga was frequently isolated as part of a polymicrobial infection with other oral flora. There was only one death in the nonimmunocompromised group. In contrast, of 15 immunocompromised patients with 16 episodes of bacteremia due to Capnocytophaga, 87% had leukopenia and 73% had significant oral pathology such as gingivitis, mucositis, or ulceration. Five immunocompromised patients died. Thus, Capnocytophaga species may cause disease in both nonimmunocompromised and immunocompromised hosts. Isolation of this organism should suggest an oral source for infection.

Entities:  

Mesh:

Year:  1985        PMID: 3965585     DOI: 10.1093/infdis/151.1.140

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

1.  Inhibition of Prevotella and Capnocytophaga immunoglobulin A1 proteases by human serum.

Authors:  E V Frandsen; M Kjeldsen; M Kilian
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  Capnocytophaga lung abscess in a patient with metastatic neuroendocrine tumor.

Authors:  Raghu Thirumala; Urania Rappo; N Esther Babady; Mini Kamboj; Mohit Chawla
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

3.  Genetic analysis of an ambler class A extended-spectrum beta-lactamase from Capnocytophaga ochracea.

Authors:  Anne Jolivet-Gougeon; Zohreh Tamanai-Shacoori; Laurent Desbordes; Nathalie Burggraeve; Michel Cormier; Martine Bonnaure-Mallet
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

Review 4.  Mixed bacteremia with Capnocytophaga sputigena and Escherichia coli following bone marrow transplantation: case report and review.

Authors:  J I García-Cía; J Esteban; F Santos-O'Connor; A Román; F Soriano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-08       Impact factor: 3.267

5.  Antimicrobial susceptibilities and beta-lactamase characterization of Capnocytophaga species.

Authors:  D L Roscoe; S J Zemcov; D Thornber; R Wise; A M Clarke
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

6.  Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena.

Authors:  Hélène Guillon; François Eb; Hedi Mammeri
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

7.  Etiologic diagnosis of Capnocytophaga canimorsus meningitis by broad-range PCR.

Authors:  J Gottwein; R Zbinden; R C Maibach; T Herren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-02       Impact factor: 3.267

8.  B-Cell deficiency predisposes mice to disseminating anaerobic infections: protection by passive antibody transfer.

Authors:  L Hou; H Sasakj; P Stashenko
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

9.  Sensitivity of Capnocytophaga species to bactericidal properties of human serum.

Authors:  M E Wilson; R Burstein; J T Jonak-Urbanczyk; R J Genco
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

10.  Bactericidal activities of synthetic human leukocyte cathepsin G-derived antibiotic peptides and congeners against Actinobacillus actinomycetemcomitans and Capnocytophaga sputigena.

Authors:  K T Miyasaki; A L Bodeau; J Pohl; W M Shafer
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.